Keywords:
Chlorpheniramine Maleate, Chlorpheniramine Maleate's R&D Progress, Mechanism of Action for Chlorpheniramine Maleate, drug target for Chlorpheniramine Maleate.
Description:
This article summarized the latest R&D progress of Chlorpheniramine Maleate, the Mechanism of Action for Chlorpheniramine Maleate, and the drug target R&D trends for Chlorpheniramine Maleate.
Text:
Chlorpheniramine Maleate's R&D Progress
Chlorpheniramine Maleate is a small molecule drug that primarily targets the H1 receptor. It has been approved for use in various therapeutic areas, including immune system diseases, infectious diseases, cardiovascular diseases, otorhinolaryngologic diseases, respiratory diseases, skin and musculoskeletal diseases, and other diseases. The drug has shown efficacy in treating conditions such as oedema vascular, angioedema, eczema, skin diseases, dermatitis, drug eruptions, hypersensitivity, edema, pruritus, respiratory tract infections, allergic rhinitis, seasonal allergic rhinitis, vasomotor rhinitis, urticaria, and even COVID-19.
Chlorpheniramine Maleate was first approved in the United States in July 1949, making it a well-established drug with a long history of use. The originator organization behind this drug is Schering Plough A/S. It is worth noting that Chlorpheniramine Maleate has reached the highest phase of approval globally, indicating its widespread acceptance and recognition in the pharmaceutical industry.
As a small molecule drug, Chlorpheniramine Maleate is designed to interact with the H1 receptor, which is involved in various immune and inflammatory responses. By targeting this receptor, the drug can effectively alleviate symptoms associated with immune system diseases, infectious diseases, and other related conditions. Its approval for use in cardiovascular diseases suggests that it may have additional benefits in managing certain heart-related conditions.
The drug's approval for otorhinolaryngologic diseases, respiratory diseases, and skin and musculoskeletal diseases highlights its versatility in treating a wide range of conditions affecting these areas. This suggests that Chlorpheniramine Maleate may have anti-inflammatory and antihistamine properties, making it a valuable therapeutic option for patients with various allergic and inflammatory disorders.
Furthermore, the inclusion of COVID-19 as an active indication for Chlorpheniramine Maleate suggests that it may have potential in managing symptoms associated with this viral infection. However, further research and clinical trials are needed to fully understand its efficacy in treating COVID-19.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Chlorpheniramine Maleate: H1 receptor antagonists
H1 receptor antagonists, also known as antihistamines, are a class of drugs that block the action of histamine at the H1 receptors. Histamine is a chemical released by the body during an allergic reaction, causing symptoms such as itching, sneezing, runny nose, and watery eyes. H1 receptor antagonists work by binding to the H1 receptors and preventing histamine from binding to these receptors, thereby reducing or preventing the allergic response.
From a biomedical perspective, H1 receptor antagonists are commonly used to treat various allergic conditions, including hay fever (allergic rhinitis), hives (urticaria), and allergic conjunctivitis. They can also be used to alleviate symptoms of allergic reactions to medications or insect bites. Additionally, some H1 receptor antagonists have sedative effects and are used as sleep aids.
It's important to note that there are different generations of H1 receptor antagonists, with varying degrees of sedation and side effects. First-generation antihistamines, such as diphenhydramine and chlorpheniramine, have more sedating properties and can cause drowsiness. Second-generation antihistamines, such as loratadine and cetirizine, are less sedating and are preferred for long-term use.
Overall, H1 receptor antagonists play a crucial role in managing allergic reactions and providing relief from associated symptoms.
Drug Target R&D Trends for Chlorpheniramine Maleate
The H1 receptor, also known as the histamine H1 receptor, plays a crucial role in the human body. It is primarily found in smooth muscle cells, endothelial cells, and nerve cells. Activation of the H1 receptor by histamine leads to various physiological responses, including vasodilation, increased vascular permeability, bronchoconstriction, and stimulation of sensory nerve endings. These responses are involved in allergic reactions, inflammation, and immune responses. Antagonists of the H1 receptor, commonly known as antihistamines, are widely used to treat allergies, hay fever, and other conditions associated with excessive histamine release. Understanding the role of the H1 receptor is essential for developing effective treatments for allergic and inflammatory disorders.
According to Patsnap Synapse, as of 10 Oct 2023, there are a total of 271 H1 receptor drugs worldwide, from 290 organizations, covering 138 indications, and conducting 1766 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
Overall, Chlorpheniramine Maleate is a well-established small molecule drug that targets the H1 receptor and has been approved for use in multiple therapeutic areas. Its long history of use, widespread approval, and broad range of indications make it a valuable asset in the pharmaceutical industry.
